In last trading session, Climb Bio Inc (NASDAQ:CLYM) saw 0.46 million shares changing hands with its beta currently measuring -0.24. Company’s recent per share price level of $1.47 trading at $0.03 or 2.08% at ring of the bell on the day assigns it a market valuation of $98.93M. That closing price of CLYM’s stock is at a discount of -685.71% from its 52-week high price of $11.55 and is indicating a premium of 4.76% from its 52-week low price of $1.40.

Climb Bio Inc (NASDAQ:CLYM) trade information

Upright in the green during last session for gaining 2.08%, in the last five days CLYM remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $1.47 price level, adding 8.7% to its value on the day. Climb Bio Inc’s shares saw a change of -18.33% in year-to-date performance and have moved -7.55% in past 5-day. Climb Bio Inc (NASDAQ:CLYM) showed a performance of -21.39% in past 30-days.

Climb Bio Inc (CLYM) estimates and forecasts

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -46.72% during past 5 years.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 899.65 shares of worth $1.32 million or 1.34% of the total outstanding shares. The later fund manager was in possession of 784.67 shares on Nov 30, 2024 , making its stake of worth around $1.15 million in the company or a holder of 1.17% of company’s stock.